Skip to content
Clinical Trials – home
SpainBack to Spain

Clinical trials in L'hospitalet De Llobregat – page 116

3 655 clinical trials in L'hospitalet De Llobregat, Spain across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
L'hospitalet De Llobregat at a glance
3 655
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

3 655 trials in L'hospitalet De Llobregat

Open in trial search

Study of elranatamab, mezigdomide and dexamethasone in patients with relapsed/refractory multiple myeloma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Elranatamab
  • Sponsor:Fundacion Pethema

Safety and efficacy of efimosfermin alfa versus placebo in adults with compensated cirrhosis (stage F4) due to MASH

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Non-small cell lung cancer+1

Not yet recruiting

Study of setidegrasib (ASP3082) and docetaxel in patients with KRAS G12D‑mutated advanced/metastatic NSCLC after platinum chemo and checkpoint inhibitor

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:ASP3082
  • Sponsor:Astellas Pharma Global Development Inc.

Alcoholic liver disease

Not yet recruiting

Safety and Efficacy of Efimosfermin Alfa vs Placebo in Adults with Alcohol-Related Liver Disease

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Breast cancer+1

Not yet recruiting

Long‑term safety study of alpelisib alone or with fulvestrant in adults with breast cancer who benefited from previous alpelisib treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Novartis Pharma AG

Study of efimosfermin alfa versus placebo in adults with compensated cirrhosis from metabolic dysfunction-associated steatohepatitis (MASH)

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Adenocarcinoma pancreas

Not yet recruiting

First‑Line Study of Zoldonrasib (RMC‑9805) Drug Combination vs Gemcitabine/Nab‑Paclitaxel in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Daraxonrasib
  • Sponsor:Revolution Medicines Inc.

A Phase 2 Study of LAD603 in Adults with Systemic Lupus Erythematosus and Active Skin Rash

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:LAD603
  • Sponsor:Almirall S.A.

Phase 2 Randomized Trial of Oral NS-863 in Patients with Pulmonary Arterial Hypertension

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:NS-863
  • Sponsor:Ns Pharma Inc.

Plasma cell myeloma

Not yet recruiting

A Phase III Study of AZD0120 versus melphalan hydrochloride with lenalidomide maintenance in transplant‑eligible adults with newly diagnosed multiple myeloma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:AZD0120
  • Sponsor:AstraZeneca AB

Safety and Efficacy of Extended‑Release Tacrolimus (VI‑0106) in Adults with Pulmonary Arterial Hypertension and Functional Limitations

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Tacrolimus
  • Sponsor:Vivus B.V.

Primary biliary cholangitis

Not yet recruiting

Safety and Efficacy of Saroglitazar Magnesium in Patients with Primary Biliary Cholangitis: A Long‑Term Randomized Placebo‑Controlled Study

Investigational
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Saroglitazar hemimagnesium
  • Sponsor:Zydus Therapeutics Inc.

Other cities in Spain

The busiest research cities in the country

All 203 cities in Spain

Clinical research in L'hospitalet De Llobregat

What the registry says about research in the country

01 Infectious Disease Prevention

Innovative research focused on vaccine development targeting multiple infectious diseases, including studies on UTI prevention, yellow fever, and RSV protection in adults.

  • UTI Vaccine Safety & Efficacy
  • Yellow Fever Immunization
  • RSV Protection Studies

These trials aim to enhance vaccine effectiveness and improve public health outcomes through preventive measures.

02 Oncology Research

Comprehensive studies exploring new treatments for various types of advanced cancers, with particular focus on targeted therapies and novel drug combinations.

  • Colorectal Cancer Treatment
  • Gastric Cancer Therapies
  • Pancreatic Cancer Interventions

Advanced clinical research investigating innovative approaches to combat various forms of cancer.

03 Transplant Medicine

Groundbreaking research in kidney transplantation, focusing on preventing rejection and improving post-transplant outcomes.

  • Antibody-Mediated Rejection
  • Delayed Graft Function
  • Novel Immunosuppressive Approaches

Studies aimed at enhancing transplant success rates and patient recovery.

04 Autoimmune Conditions

Clinical investigations into treatments for various autoimmune disorders, including innovative therapies for inflammatory conditions.

  • Psoriatic Arthritis Treatment
  • Atopic Dermatitis Management
  • Myasthenia Gravis Therapy

Focused on developing targeted treatments to improve patient quality of life.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.